The rapidly acting antidepressants ketamine and scopolamine exert behavioral effects that can last from several days to more than a week in some patients. The molecular mechanisms underlying the maintenance of these antidepressant effects are unknown. Here we show that methyl-CpG-binding protein 2 (MeCP2) phosphorylation at Ser421 (pMeCP2) is essential for the sustained, but not the rapid, antidepressant effects of ketamine and scopolamine in mice. Our results reveal that pMeCP2 is downstream of BDNF, a critical factor in ketamine and scopolamine antidepressant action. In addition, we show that pMeCP2 is required for the long-term regulation of synaptic strength after ketamine or scopolamine administration. These results demonstrate that pMeCP2 and associated synaptic plasticity are essential determinants of sustained antidepressant effects.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338784 | PMC |
| http://dx.doi.org/10.1038/s41593-021-00868-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis.
Mol Psychiatry
February 2025
Molecular Psychiatry Lab, Department of Medicine, University of Fribourg, Fribourg, Switzerland.
Article Synopsis
- A meta-analysis was conducted to evaluate whether psychoplastogens like ketamine and psychedelics increase peripheral BDNF levels in humans, which have been suggested as biomarkers for neuroplasticity.
- The analysis included data from 29 studies and found no significant evidence that these substances elevate peripheral BDNF levels, regardless of various factors such as drug type, dosage, or participant characteristics.
- The findings imply that peripheral BDNF may not be a reliable marker for assessing neuroplasticity changes in humans after psychoplastogen administration, highlighting potential discrepancies between preclinical and human studies.
A causal model for predicting the impact of pharmacotherapy on colorectal surgery outcomes.
World J Surg
December 2024
Mercer University School of Medicine, Columbus, Georgia, USA.
Introduction: Evidence-based principles in enhanced recovery programs (ERPs) demonstrate substantial improvement in patient outcomes. Determining which latent variables predict composite outcomes could refine ERP pharmacotherapy recommendations.
Methods: Using R, pharmacotherapy data were modeled from an existing dataset of adult elective colorectal surgery patients.
Ruthenium(II) N-heterocyclic carbene polymer based sensors for detection of predatory drugs like ketamine and scopolamine.
Dalton Trans
November 2024
Centre for Nano and Material Sciences, Jain University, Jain Global Campus, Kanakapura, Ramanagaram, Bangalore 562112, India.
Article Synopsis
- There is a pressing need for a sensitive and quick method to detect ketamine and scopolamine, commonly used in drug-facilitated sexual assaults.
- Researchers developed electrochemical sensors using N-heterocyclic carbene-coordinated ruthenium polymers combined with multi-walled carbon nanotubes, achieving high sensitivities for both drugs.
- The sensors demonstrate remarkable selectivity and low detection limits, making them promising tools for on-site detection in forensic investigations of date rape drugs.
Novel multi-modal methodology to investigate placebo response in major depressive disorder.
J Affect Disord
January 2025
McLean Hospital, Belmont, MA, United States of America.
Article Synopsis
- Scientists want to understand how the placebo effect works in people with major depressive disorder (MDD) because it's getting stronger in clinical trials, making it harder to find out if new treatments really work.
- They believe that studying how dopamine (a chemical in the brain related to rewards and pleasure) affects the placebo response could help find out who benefits from treatments and improve mental health care.
- The researchers set up a special clinical trial to explore this idea, using different methods to look at how the brain's reward system might influence the placebo effect in people with depression.
Depression and the Glutamate/GABA-Glutamine Cycle.
Curr Neuropharmacol
October 2024
Department of Psychiatry, Baycrest Hospital, University of Toronto, Toronto, Ontario, Canada.
Many features of major depressive disorder are mirrored in rodent models of psychological stress. These models have been used to examine the relationship between the activation of the hypothalamic- pituitary axis in response to stress, the development of oxidative stress and neuroinflammation, the dominance of cholinergic neurotransmission and the associated increase in REM sleep pressure. Rodent models have also provided valuable insights into the impairment of glycolysis and brain glucose utilization by the brain under stress, the resulting decrease in brain energy production and the reduction in glutamate/GABA-glutamine cycling.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!